Covid-19 claims an­oth­er PDU­FA vic­tim as Glax­o­SmithK­line push­es back planned PD-1 roll­out

Bris­tol My­ers Squibb isn’t the on­ly phar­ma gi­ant that’s been stand­ing in the FDA’s wait­ing line for site in­spec­tions.

Glax­o­SmithK­line is telling us to­day that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER